China's biological influenza virus split vaccine has passed WHO pre certification
According to the official WeChat account of China Biotech, on October 20, 2023, the influenza virus split vaccine produced by China National Pharmaceutical Group Changchun Institute of Biological Products passed the pre certification of the World Health Organization (WHO). As the first influenza vaccine in China to pass the pre certification of the World Health Organization, it marks that the production, manufacturing, and quality management level of China's biological influenza vaccine has been at the forefront of the world...
Tech >>
Zhang Wenhong's Comment on mRNA Vaccine Technology Winning the Nobel Prize: Another Underlying Technology Breakthrough that Will Bring Great Changes to the Biomedical Industry
IntroductionThe implementation of mRNA vaccine technology bypasses the nucleic acid recognition and inflammatory response formed over millions of years in humans, allowing mRNA vaccines to achieve targeted molecular expression in the body. This technology is another fundamental breakthrough in human scienceThis year's Nobel Prize in Physiology or Medicine was awarded to two "heroes" in mRNA vaccine technology, Katarin Carriko and Drew Weisman...
Tech >>
106 confirmed cases! No preventive vaccine yet
On July 14th, the China Center for Disease Control and Prevention released the monitoring of monkeypox epidemic in June 2023. From June 2nd to June 30th, 2023, 106 new confirmed cases of monkeypox were reported in mainland China (excluding Hong Kong, Macao, and Taiwan)...
Tech >>
Multiple cases have been discovered! Good news from the development of this vaccine
On July 13, the application for clinical trial of replication defective monkeypox vaccine independently developed by Sinopharm China Biotech Beijing Institute of Biological Products was officially accepted by the Drug Evaluation Center (CDE) of the National Medical Products Administration.Monkeypox is a kind of zoonotic viral disease caused by Monkeypox virus (MPXV), which is characterized by fever, rash and Lymphadenopathy...
Tech >>
The clinical trial application for the replication deficient monkeypox vaccine developed by Chinese biotechnology has been accepted
On July 13, the application for clinical trial of replication defective monkeypox vaccine independently developed by Sinopharm China Biotech Beijing Institute of Biological Products was officially accepted by the Drug Evaluation Center (CDE) of the National Medical Products Administration.Monkeypox is a kind of zoonotic viral disease caused by Monkeypox virus (MPXV), which is characterized by fever, rash and Lymphadenopathy...
Tech >>
54% effectiveness! Is there no new vaccine available in 102 years, or will the world's first vaccine be born?
Source: Yaozhi.com official accountImage source: Photography NetworkRecently, the Bill and Melinda French Gates Foundation and the Wellcome Trust announced that they will invest 550 million dollars for the phase 3 clinical trial of the candidate vaccine M72/AS01E for tuberculosis, which is mainly used to prevent adolescents and adults from suffering from tuberculosis...
Tech >>